All posts

IMAX Corp is a Buy, says Roth Capital

Roth Capital Partners analyst Eric Handler is staying bullish on IMAX Corp (IMAX Corp Stock Quote, Charts, News, Analysts, Financials NYSE:IMAX), saying in a Tuesday report on the company that IMAX is the best way for investors to play the recovery in theatre box offices.

IMAX, which operates with four business segments in IMAX Technology Network, IMAX Technology Sales and Maintenance, New Business Initiatives and Film Distribution and Post-Production, announced earlier this month that it set a new company record for first quarter box office with $273 million, which was over $10 million above its previous record set in 2016. According to the company, a strong global mix of releases including Avatar: The Way of Water boosted global gross box office (GBO).

“The first quarter is an excellent indicator of the promise we see in 2023 — a year in which we expect to return to our record-breaking levels of box office from 2019,” said Rich Gelfond, CEO of IMAX, in a statement.

Handler said the higher than expected GBO at $273 million was above his forecast at $255 million. As a result, the analyst has raised his Q1 revenue and adjusted EBITDA estimates from $70 million to $81 million on revenue and from $26 million to $27 million on EBITDA.

Handler noted that the GBO growth was broad based, with China being the single largest market with GBO of $98 million, up 97 per cent year-over-year, followed by the International ex-China market at $96 million, up 60 per cent year-over-year. Domestic GBO was up 25 per cent to $79 million.

“We continue to view IMAX as the best way to play the box office recovery. This view reflects the company’s global footprint and its increasing exposure to local language content along with its asset light business model and strong balance sheet,” Handler wrote.

Handler said there’s a halo effect related to the success of Avatar, one which should help fuel demand for IMAX systems going forward. He estimated IMAX has had at least 20 system signings so far this year, with Japan being a particularly robust market and generating seven new signings. 

“All seven [Japanese] systems which are part of the recently signed agreement with AEON will be installed by this summer and take the company’s footprint in Japan to 48 locations (of which 31 of these locations exceed $1 million of gross box office annually, well above the circuit average),” he said.

Looking further ahead, Handler thinks IMAX will generate full 2023 revenue and EBITDA of $366.1 million and $121.7 million, respectively, and 2024 revenue and EBITDA of $399.9 million and $135.1 million, respectively.

With the update, Handler reiterated a “Buy” rating on IMAX and $24.00 target, which implied at press time a return of 15.8 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: imax
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

17 hours ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

18 hours ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

2 days ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

2 days ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

2 days ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

4 days ago